Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Short-term Investments: 2016-2024

Historic Short-term Investments for Tg Therapeutics (TGTX) over the last 9 years, with Dec 2024 value amounting to $131.1 million.

  • Tg Therapeutics' Short-term Investments fell 60.40% to $57.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.5 million, marking a year-over-year decrease of 60.40%. This contributed to the annual value of $131.1 million for FY2024, which is 5.24% up from last year.
  • As of FY2024, Tg Therapeutics' Short-term Investments stood at $131.1 million, which was up 5.24% from $124.6 million recorded in FY2023.
  • In the past 5 years, Tg Therapeutics' Short-term Investments ranged from a high of $131.1 million in FY2024 and a low of $15.9 million during FY2021.
  • For the 3-year period, Tg Therapeutics' Short-term Investments averaged around $105.0 million, with its median value being $124.6 million (2023).
  • As far as peak fluctuations go, Tg Therapeutics' Short-term Investments slumped by 69.46% in 2021, and later surged by 273.99% in 2022.
  • Yearly analysis of 5 years shows Tg Therapeutics' Short-term Investments stood at $52.0 million in 2020, then crashed by 69.46% to $15.9 million in 2021, then skyrocketed by 273.99% to $59.4 million in 2022, then surged by 109.81% to $124.6 million in 2023, then increased by 5.24% to $131.1 million in 2024.